Angus Pryor is the Founder and CEO of Dental Marketing Solutions. In April 2023, Dental Marketing Solutions won the Australian Dental Industry Award for Marketing on a second occasion, the first being in 2020.
Convened by the Australian Dental Industry Association (ADIA), the Australian Dental Industry Awards recognise excellence in the provision of quality products and services that support the work of dentists and allied oral healthcare professionals.
After receiving his latest award, Angus spoke with Australian Health Journal.
By his estimate he’s delivered over 10,000 hours of consulting to dentists in Australia and internationally. In addition to the ADIA awards, his company has been the recipient of a number of other industry awards.
To Angus marketing deals with human psychology as well being part science and part art. He proclaims, “If dentists are serious about growing their business, they need to take marketing seriously”.
Today, competition in the dental industry is at an all time high.
According to Angus, “For more than a decade now, the number of practising dentists has increased at a rate two and a half times faster than the Australian population.”
Further, Angus has seen specialists in the dental sphere getting less referrals from general practitioner dentists. As he explains, general practitioner dentists are now doing more implants in house, more wisdom teeth, and even orthodontics. For a heavily referral based business, this can significantly impact the practice.
He offers 3 options to counter this
- Seeking more referrals from other practices
- Marketing direct to consumers
- Delivering lots of education and constantly engaging general dental practice
Winning the Australian Dental Industry Award for Marketing has had a big impact to Dental Marketing Solutions. As Angus comments in closing, “Receiving the award is social proof to say, well, these guys must know something, because an independent body of their peers has assessed them and said”. He added, “Certainly it’s been good in terms of building our business.”
You Might also like
-
Pathology technology at a crossroads
The CEO of Pathology Technology Australia, Dean Whiting spoke with Australian Health Journal about the following:
– Pathology Technology Australia’s key priorities in the coming years
– Current local capability in pathology technology compared to other countries
– How the health system supports change and adoption of pathology technology
– How pathology is perceived by the public and in government as well as how developments in pathology technology are followed and understood
– Observations in the Strengthening Medicare Taskforce ReportIn the lead up to the Australian Federal Budget in May 2023, Australian Health Journal reached out to peak health industry bodies to hear about their priorities, either noted in pre-budget submissions lodged with Federal Government in January 2023 or in recent forums such as the Strengthening Medicare Taskforce.
-
State of Private Hospitals sector in Australia
During Mr Roff’s working career at APHA he has represented the private hospitals sector to nine different Federal Health Ministers and eight Prime Ministers. He believes the government should take steps to regulate the health insurance industry to protect consumers and ensure that Australians have access to affordable and comprehensive healthcare services.
-
Cardiovascular Disease Risk Guidance and Calculator get long overdue update
Cardiovascular disease (CVD) is responsible for significant morbidity and premature mortality in Australia. Ischaemic heart disease was the leading cause of death in 2020 and cerebrovascular disease was the third most common cause of death.
As the first major update to Australian CVD risk assessment guidelines in over a decade, the 2023 Australian Guideline for assessing and managing cardiovascular disease risk and associated Aus CVD Risk Calculator reflect the latest evidence on assessing, communicating, and managing CVD risk. Developed using Australian-specific data and the latest evidence, it supersedes the 2012 Guidelines for the management of absolute cardiovascular disease risk.